BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 31578141)

  • 21. Clinical utility of the Glasgow Prognostic Score in patients undergoing curative nephrectomy for renal clear cell cancer: basis of new prognostic scoring systems.
    Lamb GW; Aitchison M; Ramsey S; Housley SL; McMillan DC
    Br J Cancer; 2012 Jan; 106(2):279-83. PubMed ID: 22166802
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plasma Glycosaminoglycans as Diagnostic and Prognostic Biomarkers in Surgically Treated Renal Cell Carcinoma.
    Gatto F; Blum KA; Hosseini SS; Ghanaat M; Kashan M; Maccari F; Galeotti F; Hsieh JJ; Volpi N; Hakimi AA; Nielsen J
    Eur Urol Oncol; 2018 Oct; 1(5):364-377. PubMed ID: 31158075
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A postoperative prognostic nomogram for renal cell carcinoma.
    Kattan MW; Reuter V; Motzer RJ; Katz J; Russo P
    J Urol; 2001 Jul; 166(1):63-7. PubMed ID: 11435824
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Local Recurrence Following Resection of Intermediate-High Risk Nonmetastatic Renal Cell Carcinoma: An Anatomical Classification and Analysis of the ASSURE (ECOG-ACRIN E2805) Adjuvant Trial.
    Lee Z; Jegede OA; Haas NB; Pins MR; Messing EM; Manola J; Wood CG; Kane CJ; Jewett MAS; Flaherty KT; Dutcher JP; DiPaola RS; Uzzo RG
    J Urol; 2020 Apr; 203(4):684-689. PubMed ID: 31596672
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Features associated with recurrence beyond 5 years after nephrectomy and nephron-sparing surgery for renal cell carcinoma: development and internal validation of a risk model (PRELANE score) to predict late recurrence based on a large multicenter database (CORONA/SATURN Project).
    Brookman-May S; May M; Shariat SF; Xylinas E; Stief C; Zigeuner R; Chromecki T; Burger M; Wieland WF; Cindolo L; Schips L; De Cobelli O; Rocco B; De Nunzio C; Feciche B; Truss M; Gilfrich C; Pahernik S; Hohenfellner M; Zastrow S; Wirth MP; Novara G; Carini M; Minervini A; Simeone C; Antonelli A; Mirone V; Longo N; Simonato A; Carmignani G; Ficarra V;
    Eur Urol; 2013 Sep; 64(3):472-7. PubMed ID: 22748912
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of type I and II papillary renal cell carcinoma (RCC) and clear cell RCC.
    Waldert M; Haitel A; Marberger M; Katzenbeisser D; Ozsoy M; Stadler E; Remzi M
    BJU Int; 2008 Nov; 102(10):1381-4. PubMed ID: 18782311
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Incidence and long-term prognosis of papillary renal cancer. Results of a retrospective multicenter study].
    Waalkes S; Roos FC; Eggers H; Schumacher S; Janssen M; Wegener G; Thüroff JW; Hofmann R; Schrader M; Kuczyk MA; Schrader AJ;
    Urologe A; 2011 Sep; 50(9):1125-9. PubMed ID: 21845424
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Contemporary external validation of the Leibovich model for prediction of progression after radical surgery for clear cell renal cell carcinoma.
    Beisland C; Gudbrandsdottir G; Reisæter LA; Bostad L; Wentzel-Larsen T; Hjelle KM
    Scand J Urol; 2015 Jun; 49(3):205-10. PubMed ID: 25423093
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Integrated staging systems for conventional renal cell carcinoma: a comparison of two prognostic models.
    Martella O; Galatioto GP; Necozione S; Pomante R; Vicentini C
    Arch Ital Urol Androl; 2011 Sep; 83(3):121-7. PubMed ID: 22184835
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multimodal recurrence scoring system for prediction of clear cell renal cell carcinoma outcome: a discovery and validation study.
    Gui CP; Chen YH; Zhao HW; Cao JZ; Liu TJ; Xiong SW; Yu YF; Liao B; Cao Y; Li JY; Huang KB; Han H; Zhang ZL; Chen WF; Jiang ZY; Gao Y; Han GP; Tang Q; Ouyang K; Qu GM; Wu JT; Guo JP; Li CX; Li PX; Liu ZP; Hsieh JT; Cai MY; Li XS; Wei JH; Luo JH
    Lancet Digit Health; 2023 Aug; 5(8):e515-e524. PubMed ID: 37393162
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Microvascular and lymphovascular tumour invasion are associated with poor prognosis and metastatic spread in renal cell carcinoma: a validation study in clinical practice.
    Bedke J; Heide J; Ribback S; Rausch S; de Martino M; Scharpf M; Haitel A; Zimmermann U; Pechoel M; Alkhayyat H; Shariat SF; Dombrowski F; Stenzl A; Burchardt M; Klatte T; Kroeger N
    BJU Int; 2018 Jan; 121(1):84-92. PubMed ID: 28803448
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Outcome of papillary versus clear cell renal cell carcinoma varies significantly in non-metastatic disease.
    Wagener N; Edelmann D; Benner A; Zigeuner R; Borgmann H; Wolff I; Krabbe LM; Musquera M; Dell'Oglio P; Capitanio U; Klatte T; Cindolo L; May M; Brookman-May SD;
    PLoS One; 2017; 12(9):e0184173. PubMed ID: 28934212
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinicopathologic and molecular correlations of necrosis in the primary tumor of patients with renal cell carcinoma.
    Lam JS; Shvarts O; Said JW; Pantuck AJ; Seligson DB; Aldridge ME; Bui MH; Liu X; Horvath S; Figlin RA; Belldegrun AS
    Cancer; 2005 Jun; 103(12):2517-25. PubMed ID: 15880379
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic factors and prognostic models for renal cell carcinoma: a literature review.
    Klatte T; Rossi SH; Stewart GD
    World J Urol; 2018 Dec; 36(12):1943-1952. PubMed ID: 29713755
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The follow-up management of non-metastatic renal cell carcinoma: definition of a surveillance protocol.
    Antonelli A; Cozzoli A; Zani D; Zanotelli T; Nicolai M; Cunico SC; Simeone C
    BJU Int; 2007 Feb; 99(2):296-300. PubMed ID: 17326263
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system.
    Lam JS; Shvarts O; Leppert JT; Pantuck AJ; Figlin RA; Belldegrun AS
    J Urol; 2005 Aug; 174(2):466-72; discussion 472; quiz 801. PubMed ID: 16006866
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic value of the Leibovich prognosis score supplemented by vascular invasion for clear cell renal cell carcinoma.
    Pichler M; Hutterer GC; Chromecki TF; Jesche J; Groselj-Strele A; Kampel-Kettner K; Pummer K; Zigeuner R
    J Urol; 2012 Mar; 187(3):834-9. PubMed ID: 22245331
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Renal fossa recurrence after nephrectomy for renal cell carcinoma: prognostic features and oncological outcomes.
    Psutka SP; Heidenreich M; Boorjian SA; Bailey GC; Cheville JC; Stewart-Merrill SB; Lohse CM; Atwell TD; Costello BA; Leibovich BC; Thompson RH
    BJU Int; 2017 Jan; 119(1):116-127. PubMed ID: 27489013
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic models and algorithms in renal cell carcinoma.
    Lane BR; Kattan MW
    Urol Clin North Am; 2008 Nov; 35(4):613-25; vii. PubMed ID: 18992615
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after nephrectomy: a multicenter European study.
    Cindolo L; Patard JJ; Chiodini P; Schips L; Ficarra V; Tostain J; de La Taille A; Altieri V; Lobel B; Zigeuner RE; Artibani W; Guillé F; Abbou CC; Salzano L; Gallo C
    Cancer; 2005 Oct; 104(7):1362-71. PubMed ID: 16116599
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.